ReviewHeliyon2023
Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Organoids, organ-on-a-chip, and microtumors: Biomimetic 3D tumor models advancing drug development and precision medicine.Acta pharmaceutica Sinica. B · 2026Review
- Host Gene Signatures Associated with Gastric Cancer-Associated Microbial Taxa: A Descriptive Microbiome-Transcriptome Study.Medicina (Kaunas, Lithuania) · 2026Article
- Managing dangerous liaisons: lessons fromJournal of bacteriology · 2026Review
- Article
- The research progress of the synergistic effect of Epstein-Barr virus andFrontiers in oncology · 2026Review
- Article
- MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5.Scientific reports · 2025Article
- Hypermethylation-mediated HNF4A silencing by Helicobacter pylori infection drives gastric cancer by disrupting epithelial cell polarity and activating EMT signaling.Cell death & disease · 2025Article
- The Potential Role ofMicroorganisms · 2025Review
- From lab to life: technological innovations in transforming cancer metastasis detection and therapy.Discover oncology · 2025Review
- Article
- Review
- Article
- Multi-omics analysis of parthanatos related molecular subgroup and prognostic model development in stomach adenocarcinoma.PloS one · 2025Article
- Microbiome in cancer metastasis: biological insights and emerging spatial omics methods.Frontiers in cellular and infection microbiology · 2025Review
- EFHD1 Activates SIK3 to Limit Colorectal Cancer Initiation and Progression via the Hippo Pathway.Journal of Cancer · 2025Article
- Gastrointestinal cancer resistance to treatment: the role of microbiota.Infectious agents and cancer · 2024Review
- The spatiotemporal associations between esophageal and gastric cancers provide evidence for its joint endoscopic screening in China: a population-based study.BMC medicine · 2024Article
- An aptamer and Au/Si CCA based SERS sensor for ultra-sensitive detection of Vimentin during EMT in gastric cancer.Frontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer, a multifactorial disease, is considered one of the most common malignancies worldwide. In addition to genetic and environmental risk factors, infectious agents, such as Epstein-Barr virus (EBV) and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.